Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology

Josep M Llovet1, Mathias Heikenwalder2

  • 1Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.

Gastroenterology
|April 28, 2023
PubMed
Abstract

No abstract available in PubMed .